← Full evidence page

For the cleanest result, disable browser headers and footers.

Dediabetes Evidence Brief

Diabetic Kidney Disease: Evidence-Based Treatments and Outcomes

Evidence related to diabetic kidney disease, albuminuria, kidney function, nephropathy progression, end-stage renal disease, and kidney-protective diabetes treatments.

Latest indexed publication
June 2026
Brief accessed
—

Full evidence pagehttps://www.dediabetes.com/evidence/diabetic-kidney-disease

Executive Summary

Diabetic Kidney Disease evidence appears to center on Dapagliflozin.

Among 9 indexed studies and 7 interventions, the strongest signals are summarized from the available evidence. Dapagliflozin appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Freshness

Latest indexed evidence: June 2026

Evidence Snapshot

Studies analyzed
9
Evidence relationships
15
Interventions
7
Outcomes
7
Strong evidence signals
0
Mixed evidence areas
0
Latest indexed publication
June 2026

Key Findings

  1. 01

    Across 2 studies, Dapagliflozin shows a consistent moderate positive signal for Urinary albumin-to-creatinine ratio.

  2. 02

    Across 1 study, Dapagliflozin shows a strong positive signal for Estimated glomerular filtration rate.

  3. 03

    Across 1 study, Dapagliflozin shows a strong positive signal for Renal and urinary disorders incidence.

  4. 04

    Across 1 study, Empagliflozin shows a neutral signal for Urinary albumin-to-creatinine ratio.

Evidence Categories

The evidence is organized by how consistently it supports a conclusion and how much research is available.

Well-Supported Interventions

The strongest and most consistent evidence for improving this outcome.

Evidence is consistently positive across multiple studies.

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

Dapagliflozin appears to have a consistent beneficial signal in the indexed evidence.

Leading examples

Dapagliflozin

Evidence basis: 4 evidence pairs - 3 studies

Findings Requiring Careful Interpretation

Results that vary across studies or depend on population, study design, duration, or comparator.

Some evidence is positive, but results are not consistent across all studies.

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Dapagliflozin is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Leading examples

Dapagliflozin · Empagliflozin · Integrated multidisciplinary diabetes and kidney care program

Evidence basis: 12 evidence pairs - 7 studies

Emerging Areas of Research

Early positive signals that require additional high-quality research.

Early findings are encouraging, but stronger trials are needed.

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Dapagliflozin may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Leading examples

Dapagliflozin · Finerenone (nonsteroidal mineralocorticoid receptor antagonist) · Pentoxifylline

Evidence basis: 10 evidence pairs - 6 studies

About this Evidence Brief

This brief summarizes research currently indexed by Dediabetes Evidence Intelligence. It is not a clinical guideline or personalized medical recommendation. Evidence classifications may change as additional studies are indexed.

Suggested citation

—